Henry Schein, Inc. (HSIC)
Henry Schein, Inc. (HSIC) Presents at Jefferies London Healthcare Conference 2025 Transcript
Henry Schein, Inc. ( HSIC ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:30 AM EST Company Participants Stanley Bergman - Executive Chairman & CEO Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Conference Call Participants Michael Sarcone - Jefferies LLC, Research Division Presentation Michael Sarcone Jefferies LLC, Research Division Hi, everyone. My name is Mike Sarcone.
Henry Schein, Inc. (HSIC) Presents at Stifel 2025 Healthcare Conference Transcript
Henry Schein, Inc. ( HSIC ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Tom Popeck - Chief Executive Officer of Henry Schein Products Group Ronald South - Senior VP & CFO Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Jonathan Block Stifel, Nicolaus & Company, Incorporated, Research Division I'm happy to introduce the team from Henry Schein. We have Ron South, CFO; Andrea Albertini, CEO of Global Distribution and Technology; and Tom Popeck, CEO of the Henry Schein Products Group.
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Henry Schein, Inc. (HSIC) Q3 2025 Earnings Call Transcript
Henry Schein, Inc. ( HSIC ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Stanley Bergman - Executive Chairman & CEO Ronald South - Senior VP & CFO Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division John Stansel - JPMorgan Chase & Co, Research Division Allen Lutz - BofA Securities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Michael Cherny - Leerink Partners LLC, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Brandon Vazquez - William Blair & Company L.L.C.
Here's What Key Metrics Tell Us About Henry Schein (HSIC) Q3 Earnings
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HSIC Stock Jumps on Q3 Earnings and Revenue Beat, '25 Outlook Up
Henry Schein's Q3 earnings and revenues top estimates, lifting the stock as the company raised its 2025 outlook on solid business momentum.
Henry Schein (HSIC) Q3 Earnings and Revenues Beat Estimates
Henry Schein (HSIC) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.22 per share a year ago.
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Henry Schein Is Placed Ahead of Q3 Earnings
HSIC heads into Q3 with solid gains expected across Dental, Specialty and Tech segments, though earnings estimates have slipped slightly.
Henry Schein, Inc. (HSIC) Presents At Baird Global Healthcare Conference 2025 Transcript
Henry Schein, Inc. (NASDAQ:HSIC ) Baird Global Healthcare Conference 2025 September 10, 2025 10:50 AM EDT Company Participants Stanley Bergman - Executive Chairman & CEO Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Tom Popeck - Chief Executive Officer of Henry Schein Products Group Ronald South - Senior VP & CFO Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst All right.
Henry Schein: The Case For An Upgrade From Hold To Buy
Henry Schein is transitioning to higher-margin businesses, with strong tailwinds in dental and medical markets, and is now fairly valued after previous overvaluation. KKR's strategic investment and restructuring support, plus resolution of past issues like the cyber incident, position HSIC for margin improvement and renewed growth. Despite recent stagnation, margin compression, and tariff headwinds, management is actively addressing challenges through efficiency initiatives and product mix shifts.
